The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis
The efficacy and safety of rivaroxaban in coronary artery disease patients with heart failure and sinus rhythm: a systematic review and meta-analysis
复制标题
利伐沙班治疗伴有心力衰竭和窦性心律的冠心病患者的疗效和安全性：系统评价和荟萃分析
DOI：
10.1007/s00228-021-03195-w
复制
发表时间：
2021
影响因子：
2.9
通讯作者：
Weifang Zhang
中科院分区：
文献类型：
--
作者：
Shan;Jingjing Chen;Gang Xiong;Juan Li;J. Wan;Ye Liu;Ruilai Xu;Weifang Zhang
目的探讨利伐沙班治疗冠心病心力衰竭窦性心律的有效性和安全性。使用PubMed、科克伦图书馆、Embase、CNKI和万方数据库进行了自成立至2021年2月的全面文献检索。随机对照试验（RCT）的重点是新的口服抗凝剂（NOAC）治疗的有效性和安全性的CAD和HF患者的SR是合格的。使用R编程语言进行统计分析。最终分析了3项RCT，包括10，658例接受抗血小板药物治疗（伴或不伴利伐沙班）的成人患者。平均随访20.4 ~ 24个月。利伐沙班在心肌梗死（MI）和卒中中具有有利的点估计值（MI利伐沙班组（3.83%，203/5306）vs. APT组）（4.52%，214/4731），RR = 0.78，95%CI 0.65-0.94，P < 0.01，I2 = 0%），卒中：利伐沙班组（1.60%，85/5306）vs. APT组（2.52%，119/4731），RR = 0.64，95%CI 0.49-0.85，P < 0.01，I2 = 12%）。利伐沙班在全因死亡和大出血方面与安慰剂相当（全因死亡：利伐沙班组（12.27%，688/5606）vs. APT组（14.59%，737/5052），RR = 0.73，95%CI 0.49-1.06，P > 0.05，I2 = 87%），（大出血：利伐沙班组（1.52%，85/5586）vs. APT组（1.37%，69/5043），RR = 1.18，95%CI 0.86-1.62，P > 0.05，I2 = 0%）。在患有CAD和HF的SR患者中，利伐沙班联合APT的MI和卒中发生率低于单独APT，两种治疗的全因死亡和大出血发生率相似。
To explore the efficacy and safety of rivaroxaban in patients with coronary artery disease (CAD), heart failure (HF) and sinus rhythm (SR). Comprehensive literature searches were conducted using the PubMed, Cochrane Library, Embase, CNKI and Wanfang databases from inception to February 2021. Randomized controlled trials (RCTs) focusing on the efficacy and safety of new oral anticoagulant (NOAC) therapy in CAD and HF patients in SR were eligible. Statistical analyses were performed using R Programming Language. Three RCTs included 10,658 adult patients treated with antiplatelet drugs with or without rivaroxaban were ultimately analysed. The average follow-up period was 20.4–24 months. Rivaroxaban had a favourable point estimate in myocardial infarction (MI) and stroke (MI rivaroxaban group (3.83%, 203/5306) vs. APT group (4.52%, 214/4731), RR = 0.78, 95% CI 0.65–0.94, P < 0.01, I2 = 0%), (stroke: rivaroxaban group (1.60%, 85/5306) vs. APT group (2.52%, 119/4731), RR = 0.64, 95% CI 0.49–0.85, P < 0.01, I2 = 12%) compared with the placebo. Rivaroxaban was comparable to the placebo for all-cause death and major bleeding (all-cause death: rivaroxaban group (12.27%, 688/5606) vs. APT group (14.59%, 737/5052), RR = 0.73, 95% CI 0.49–1.06, P > 0.05, I2 = 87%), (major bleeding: rivaroxaban group (1.52%, 85/5586) vs. APT group (1.37%, 69/5043), RR = 1.18, 95% CI 0.86–1.62, P > 0.05, I2 = 0%). In SR patients with CAD and HF, the rates of MI and stroke associated with rivaroxaban combined with APT were lower than those associated with APT alone, and the two treatments had similar rates of all-cause death and major bleeding.
影响因子：
24
作者：
January, Craig T.;Wann, L. Samuel;Yancy, Clyde W.
通讯作者：
Yancy, Clyde W.